Moderna reported third-quarter 2026 revenue growth of 29% and a return to profitability, with $200 million in net income. Management credited higher mNEXSPIKE adoption in the US and partnerships in the UK and Canada. Cash costs fell 10% from a year earlier. The company raised its full-year revenue growth guidance to 15% to 25%, from up to 10%. It plans to submit a Biologics License Application for Intismeran in melanoma by the end of 2026, aiming for approval in 2027. A Phase 3 trial showed a 42% reduction in risk of recurrence or death versus KEYTRUDA alone. Moderna raised $3 billion through a 0% convertible note to fund oncology growth. It paused enrollment in its norovirus vaccine programme after an interim analysis missed statistical criteria for early success.

Moderna shares jumped 8% after the company beat third-quarter estimates and raised its 2026 revenue growth outlook to 15%-25%. Revenue rose 29% to $1.31 billion, against analyst expectations of $885 million. Of that, $533 million came from outside the US, mostly Covid vaccine sales under long-term government deals with the UK, Canada, and Australia. Chief executive officer Stéphane Bancel told CNBC: "The new product and the diversification of geography is what has led to such a strong Q3." Rivals fared worse. Pfizer's Comirnaty sales fell 29% operationally, and BioNTech's revenue fell 15% to €1.29 billion. Moderna still trades near its five-year high on forward sales, driven by hopes for its cancer vaccine intismeran, developed with Merck.

Today's top movers: tech rebounds as weak outlooks trigger mass selloffs. Market volatility peaked this morning as investors bought the dip. Tech giants and companies with upgraded 2026 outlooks like Moderna and Airbnb successfully reattracted investor capital. On the other hand, missed Wall Street targets and full-year guidance cuts dragged down the stocks of DraftKings, Axon, and Globus Medical. Published on 11/06/2026 at 11:21 am EST MarketScreener.com AMD (+8.40%): Traders chose to "buy the dip" on the stock today after a massive selloff in the tech sector yesterday. This was part of a broader upswing in the technology sector, with Micron Technology and Nvidia also surging 6.93% and 5.6%. The company posted robust Q3 earnings on Tuesday, as revenue rose to $13.38bn, up 44.5% from $9.25bn a year earlier, and surpassing analysts' target of $13.10bn. Airbnb (+8.5%): Shares jumped after the company reported a stronger-than-expected increase in Q3 earnings and revenue. The online service beat third quarter earnings per share of $3.16 vs analysts' consensus of $2.85, with revenue growth at its fastest pace in over three years. The firm unveiled a $12bn share buyback, and lifted its 2026 outlook. Moderna (+9.1%): The biotechnology company raised its 2026 revenue growth forecast. Moderna now expects total revenue growth of 15%-25% for the year, up from a previous outlook for up to 10% growth. Its Q3 earnings topped Wall Street's estimates with total revenue jumping 29% to $1.31bn year over year. Analysts expected $890.3m. The company attributed the gain to increasing Covid-19 vaccine sales in international markets. DraftKings (-28.3%): The entertainment company plunged this morning, as it reported a Q3 adjusted loss of $0.53 per diluted share, widening from the loss of $0.26 a year earlier. The extended loss disappointed analysts, who expected $0.13. Revenue growth also missed Wall Street forecasts. Revenue in the three months ended Sept. 30 rose to $1.33bn from $1.14bn a year earlier, when analysts projected $1.39bn. The firm also cut its full-year revenue guidance to $6.35bn-$6.55bn from the previous outlook of $6.5-bn-$6.9bn. Axon Enterprise (-18,2%): The Taser brand lowered its annual revenue growth forecast to $3.61bn-$3.63bn, a reduction from prior guidance of approximately 32%-34%. The company missed analysts estimates of $3.71bn. It cited an "exclusion of three Federal Dedrone deployments totaling about $130 million" to justify the cut. Globus Medical (-12,5%): The shares of the global musculoskeletal firm fell this morning as its Q3 revenue dropped, from $769m a year ago to $763.7m currently. It also trimmed its full-year 2026 revenue outlook to $3.09bn, compared with previous guidance of $3.18bn-$3.22bn. (C) MarketScreener.com - 2026